Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and The DNA damage-signaling pathway has been implicated in the development of prostate cancer. Germline mutations in several genes (BRCA 1, BRCA2, and CHEK2) whose products are involved in this pathway have been associated with increased risk for this disease. To identify additional genes in this pathway that might confer susceptibility to prostate cancer, we isolated a p73 upregulated gene (p73R1) and screened this gene for mutations in prostate cancer. Two germline truncating mutations were identified. Genotyping of 403 men with sporadic prostate cancer for the two mutations showed a frequency of 3.2% (13/403) in contrast to 0.6% (2/327) in 327 population-based controls (Fisher's exact test, P = 0.016), with an odds ratio of 5.4 (95% confidence interval 1.2 -24.2). Analyses of 994 affected men from 444 familial prostate cancer families showed a relatively lower frequency of 1.6% but no mutations were found in 100 unaffected men from these families, indicating a similar trend observed for other comparisons. Overall, our data suggest that germline p73R1 truncating mutations may predispose men to prostate cancer and further supports the concept that the mutant alleles in the DNA damage-response genes play an important role in the development of sporadic prostate cancer. Introduction: Prostate cancer is a complex genetic disease and its etiology very likely involves many genetic loci with no major gene with high penetrance. To identify such prostate cancer susceptibility genes, we have been using a novel approach based on mutation screening of candidate genes involved in the DNA damagesignaling pathway. Genomic instability is a common feature of all human cancers. The DNA damagesignaling pathway plays a critical role in maintaining genomic stability in response to DNA damage. The integrity of this pathway is essential for the prevention of neoplastic transformation, since several proteins involved in this pathway (such as p53, BRCA1, and ATM) are frequently mutated in human cancer. In a search for p73-dependent DNA damage-responsive genes, we isolated a p73-upregulated gene (p73R1) which is identical to the p53AIP1 gene (ref. 1) that is activated by cisplatin-induced DNA damage. We have identified several deleterious germline mutations in this gene in approximately 3.2% (17/532) of primary or sporadic prostate cancer but only in 0.6% (2/331) of unaffected men (Fisher's exact test, P = 0.016). We, therefore, propose to study in detail the involvement of this gene in familial prostate cancer families which will be the first step towards providing evidence that p73R1 is a prostate cancer susceptibility gene. The objective of this project is to identify the genetic role of p73R1 in prostate cancer development and to determine the functions and mechanisms of p73R1 in tumorigenesis. Our hypothesis is that p73R1 is a candidate prostate cancer susceptibility gene. Three Aims for this proposal are: (1) To determine whether p73R1 mutations co-segregate with prostate cancer phenotype in familial prostate cancer families; (2) to explore whetherp73R1 mutations are associated with any clinical and pathological characteristics in patients with prostate cancers; and (3) to determine the functional role of p73R1 in tumorigenesis. We have developed an accurate and sensitive Denaturing HPLC protocol to detectp73R1 mutations. We will screen forp73R1 mutations in 163 familial prostate cancer families and in 1,000 tumor samples collected at Mayo Clinic. Model-free genetic linkage analysis and statistical analysis will be performed to determine the co-segregation of p73R1 mutations in prostate cancer families and any clinicopathological significance in patients with mutations and those without. p73R1 mutants will be generated and expressed in mammalian cell systems to determine if the mutations fail to induce apoptosis and suppress cell growth.
Introduction: Prostate cancer is a complex genetic disease and its etiology very likely involves many genetic loci with no major gene with high penetrance. To identify such prostate cancer susceptibility genes, we have been using a novel approach based on mutation screening of candidate genes involved in the DNA damagesignaling pathway. Genomic instability is a common feature of all human cancers. The DNA damagesignaling pathway plays a critical role in maintaining genomic stability in response to DNA damage. The integrity of this pathway is essential for the prevention of neoplastic transformation, since several proteins involved in this pathway (such as p53, BRCA1, and ATM) are frequently mutated in human cancer. In a search for p73-dependent DNA damage-responsive genes, we isolated a p73-upregulated gene (p73R1) which is identical to the p53AIP1 gene (ref. 1) that is activated by cisplatin-induced DNA damage. We have identified several deleterious germline mutations in this gene in approximately 3.2% (17/532) of primary or sporadic prostate cancer but only in 0.6% (2/331) of unaffected men (Fisher's exact test, P = 0.016). We, therefore, propose to study in detail the involvement of this gene in familial prostate cancer families which will be the first step towards providing evidence that p73R1 is a prostate cancer susceptibility gene. The objective of this project is to identify the genetic role of p73R1 in prostate cancer development and to determine the functions and mechanisms of p73R1 in tumorigenesis. Our hypothesis is that p73R1 is a candidate prostate cancer susceptibility gene. Three Aims for this proposal are: (1) To determine whether p73R1 mutations co-segregate with prostate cancer phenotype in familial prostate cancer families; (2) to explore whetherp73R1 mutations are associated with any clinical and pathological characteristics in patients with prostate cancers; and (3) to determine the functional role of p73R1 in tumorigenesis. We have developed an accurate and sensitive Denaturing HPLC protocol to detectp73R1 mutations. We will screen forp73R1 mutations in 163 familial prostate cancer families and in 1,000 tumor samples collected at Mayo Clinic. Model-free genetic linkage analysis and statistical analysis will be performed to determine the co-segregation of p73R1 mutations in prostate cancer families and any clinicopathological significance in patients with mutations and those without. p73R1 mutants will be generated and expressed in mammalian cell systems to determine if the mutations fail to induce apoptosis and suppress cell growth. Body: The tasks, which we proposed to fulfill in Year 1 and the accomplishments associated with each task, are summarized below: Specific Aim 1: To identify p73R1 mutations and to study the segregation of these mutations in familial CaP: We will screen for p73R1 mutations in 163 families with familial CaP to determine whether the mutations segregate with the CaP phenotype.
In our preliminary study, we identified two truncating germline p73R1 mutations (Ser32Stop and Arg2linsG) in sporadic prostate cancer and in clinical CaP tissues. We showed that these mutations associated with prostate cancer risk by comparison between 400 men with sporadic CaP and 331 unaffected men (Fisher's exact test, P = 0.0 16), with an odds ratio of 5.5 (95% confidence interval 1.2-24.7) ( Table.1 ). In addition, these two truncating mutations were not detected in any of the 403 non-prostate tumor specimens including 127 breast cancer, 110 ovarian cancer, 72 gastric cancer, and 94 neuroblastomas ( Table 1 ), suggesting that the p73R1 truncating mutations are probably specific for prostate cancer. The familial, sporadic CaP cases, and the unaffected men controls used in this study are described in one of our previous publications (see ref.
2). In the last year, we completed the screening for p73R1 mutations in all family members of 166 prostate cancer families collected at Mayo Clinic. A total of 596 individuals from these families, including 440 affected men, 55 unaffected men, and 101 females, were analyzed (Table 2 ). We detected 6 Arg2linsG mutations in 440 affected men but not in any unaffected men or any females in these families. The frequency of the germlinep73R1 truncating mutations in familial prostate cancer (FPC) is 1.4% (6/440). Although the mutation frequency in FPC is higher than 0.6% (2/327) in population-based controls, it is much lower than 3.2% (13/403) in sporadic prostate cancer as we previously studied. In addition, the six Arg2l insG mutations were detected in six unrelated families, indicating that the p73R1 mutations are not likely associated with FPC. Since the average number of affected men in our FPC families is smaller (4.2 affected per family) than those collected at Johns Hopkins and the University of Michigan (over 5 affected per family), we collaborated with the two groups and analyzed two additional sets of FPC families from these two groups to rule out the possibility that p73R1 mutations may only confer susceptibility to large FPC families. As shown in Table 2 , we found eight p73R1 frameshift (two Ser32Stop and six Arg2linsG) mutations in 308 affected men in 134 Michigan FPC families; the frequency is 2.6%. However, we only detected 2 frameshift (one Ser32Stop and one Arg2l insG) mutations in 246 affected men from 144 Johns Hopkins FPC families; the frequency is only 0.8% (Table 2 ).
So far, we have screened forp73R1 truncating mutations in a total of 444 HPC families. We detected 16 truncating mutations in 994 (1.6%) of the affected men and no truncating mutations were detected among the 100 unaffected men from these families, (Table 2) . Although the data reflects a similar trend as that observed for other comparison, the frequency is lower than that detected in the sporadic cases (3.2%).
Other genes may play a more prominent role for prostate cancer susceptibility in the familial cases. Clearly, additional studies are needed to explain this difference.
Specific Aim 2: To determine the clinicopathological significance of p73R1 mutations in patients with sporadic CaP: We plan to screen for p73RJ mutations in an additional 1,000 unselected CaP tumor samples to determine possible associations with age, disease stage, PSA levels, aneuploidy, etc. Statistical analyses will be performed to assess the increased risk in patients with p73R1 mutations compared to those without or to 332 unaffected men in the normal population.
Since there were no obvious genetic roles of the p73R1 truncating mutations in FPC, we focused our effort on analysis of the clinicpathological significance ofp73R1 mutations in patients with sporadic CaP as we proposed in Aim 2. We have collected more than 1,000 freshly frozen prostate tumor tissues so far. These tumors are paired with normal tissues. As we proposed, we have H&E stained slides from each of the CaP. Dr. John Cheville has examined the slides and marked the tumor area on each slide. The TACMA core facility lead by Dr. Wilma Lingle has performed macrodissection on most of the tumors. Tissue slices from approximately 400 paired CaP tumor/normal have been prepared and DNAs have been isolated. We are ahead of the schedule of the proposal. We will finish the DNA isolation from 1,000 pairs of CaP by March 2005 and start mutational screening in these tumor specimens to determine the clinicopathological significance of thep73R1 mutations in prostate cancer.
Key Research Accomplishments: 1) We finished screening for germline p73R1 mutations in 994 affected men, 100 unaffected men, and 150 females from a total of 444 FPC families collected at three institutions (Mayo, Johns Hopkins, and University of Michigan). The p73R1 frameshift mutations were found in 1.6% of the affected men but in none of the 100 unaffected men in these FPC families. Our data suggest that the frequency of the p73R1 mutations in FPC (1.6%) is lower than those detected in sporadic cases (3.2%) . Although the data reflects a similar trend observed for other comparisons, other genes may play a more prominent role for prostate cancer susceptibility in the familial cases. Clearly, additional studies are needed to explain this difference.
2) We have processed about 400 pairs of unselected clinical CaP tumor and their matched normal tissues. We performed macrodissection on all of the tumor tissues and isolated the DNA from the tissue slices for further analysis of the clinicopathological impacts of the p73R1 mutations in prostate cancer, which is described in Aim 2 of this proposal.
Reportable outcomes: Germline p73R1 mutations are implicated in 3% of men with sporadic prostate cancer.
Conclusions:
We have shown that germline p73R1 truncating mutations increase risk for men to develop sporadic prostate cancer by 5-6 fold and further supports the concept that the mutant alleles in the DNA damage-response genes play an important role in the development of sporadic prostate cancer. However, analysis ofthep73R1 mutations in 444 FPC families indicate that the frequency of p73R1 mutations in FPC (1.6%) is lower than that in sporadic cases (3.2%) . Although the data reflects a similar trend observed for other comparisons. Other genes may play a more prominent role for prostate cancer susceptibility in the familial cases. Clearly, additional studies are needed to explain this difference. prostate cancer and suggested an increased risk for men with CHEK2-mutations to develop prostate cancer . Thus, it is very likely that other genes that participated in the DNA damage-signaling pathway could be targets for mutations in prostate cancer tumorigenesis.
P53AIP1 [MIM 605426
] is a downstream target of p53 and is induced by DNA damage (Oda et al. 2000) . This gene generates three transcripts (a, I0, and y) by alternative splicing. The a and P3 forms ofp53AIP1 are localized to the mitochondria and induce apoptosis through dissipation of mitochondria membrane potential (Oda et al. 2000) . The expression ofp53AIP1
and p53AIP1-induced apoptosis are closely correlated with phosphorylation of p53 at Ser-46, indicating that p53AIP1 plays an important role in mediating p53-dependent apoptosis.
Moreover, p53AIP1 interacts with bcl-2, an inhibitor of apoptosis, in mitochondria (Matsuda et al. 2002) . This event induces the release of cytochrome c from mitochondria and very likely regulates p53AIP 1-mediated apoptosis through regulation of the mitochondrial membrane potential. P73 [MIM 601990], the homolog of p53, also induces transcription of the proapoptotic gene p53AIP1 after being acetylated by p300 (Costanzo et al. 2002) . These studies suggest that p53AIP 1 is crucial for regulation of both p53-and p73-dependent DNA damagesignaling pathways and disruption of the function of p53AIP1 in p53-and p73-mediated apoptosis could play a role in cancer development. Since p73 is not mutated in prostate cancer (data not shown) and the mutation frequency in p53 is low (3-30%) in prostate cancer but much higher in other cancers, p53AIP1 could be an ideal mutation target for prostate cancer susceptibility.
To determine whether disruption of the function of p53AIP1 in the p53-or p73-dependent apoptotic pathway is associated with prostate cancer risk, we first screened p53AIPlct for mutations in 132 primary prostate tumor specimens from an unselected series of samples collected at Mayo Clinic between 1997-1998. The entire coding and exon/intron junction sequences of this gene were amplified by PCR using three primer pairs p53AIPle2F/R (5'-AAATGAGGAGAAGCCAAGTT3' and 5'CGGCACCACGGTGAGA-3'), p53AIP~e3F/R (5'-AACCATCCAAGAGACGG3' and 5'ATCACTTAATTCTATCACGG-3'), and p53AIPle4F/R (5'-AAGGACTCCATACGTTTTGC3' and 5'GCTGGAGCCATTTCTCGAC-3'). The PCR products were screened for sequence mismatches by denaturing high-performance liquid chromatography (DHPLC) followed by direct sequence analysis (Liu et al. 1998 ). Three unique non-synonymous sequence variations (C20T, Ala7Val; A304G, Arg I02Glu; C313T, Pro lO5Ser), one nonsense mutation (C95A, Ser32Stop), and one frameshift mutation due to a one base-pair insertion (64insG, Arg2l insG)( Figure 1 ) were identified. The two p53AIP1 truncating mutations (Ser32Stop and Arg2l insG) were present in 3% (4/132) of the tumor samples ( Table   1 ). The three missense mutations were present in 4.5-41% of prostate tumor specimens ( Table   1 ). All of the 5 mutations identified inp53AIP1 were present in both tumor specimens and matched normal tissues, indicating that they were germline in nature (data not shown). We then tested for the presence of these mutations within the normal population by screening for p53AIP1 mutations in 95 normal individuals. These individuals, which included 38 females and 57 males were seen at the Mayo Clinic during 1998-1999 as part of a clinical evaluation. There was no history of cancer for any of these individuals at the time of blood collection and none of the men were tested for elevated levels of PSA. Except for the three missense mutations that were detected at slightly lower frequencies than those detected in prostate tumor samples (Table 1) , we did not detect the two truncating mutations in any of the normal individuals. These data suggested that the two p53AIP1 truncating mutations are associated with prostate cancer risk.
To further evaluate the significance of the two p53AIP1 truncating mutations in the predisposition to sporadic prostate cancer, we assessed their frequencies in an additional 403 men with sporadic prostate cancer and in an additional 327 population-based controls (all male).
These two sets of samples have been previously published in other gene association studies except that 4 controls were dropped due to the occurrence of prostate cancer and 3 sporadic cases were added . The patients with sporadic prostate cancer were collected at the Mayo Clinic and were selected from respondents to a family history survey that reported no family history of prostate cancer (Schaid et al. 1998; Wang et al. 2002) .
The diagnosis of prostate cancer was confirmed by pathology reports. Prostate specific antigen (PSA) values at diagnosis were available for 326 men, with a median value of 7.2 and with 76% having values of 4 or greater. The median age for this group was 65.0 (range 46.0 -79.0). The unaffected control subjects were recruited from a sampling frame of the local population provided by the Rochester Epidemiology Project (Melton 1996) , 475 men were randomly selected for a clinical urologic examination (Oesterling et al. 1993 ). This clinical examination included digital rectal examination (DRE) and transrectal ultrasound (TRUS) of the prostate, abdominal ultrasound for post-void residual urine volume, measurement of serum levels of prostate-specific antigen (PSA) and creatinine, focused urologic physical examination, and cryopreservation of serum for subsequent sex hormone assays. Any patient with an abnormal DRE, elevated serum PSA level, or suspicious lesion on TRUS was evaluated for prostatic malignancy. If the DRE and TRUS were unremarkable but the serum PSA level was elevated (>4.0 ng/ml), then a sextant biopsy (three cores from each side) of the prostate was performed. An abnormal DRE or TRUS results, regardless of the serum PSA level, prompted a biopsy of the area in question. In addition, a sextant biopsy of the remaining prostate was performed. Those men who were found to be without prostate cancer on the basis of this extensive workup at baseline or at any of the followup examinations through 1994 were used for the control population. Three hundred and twentyseven of these individuals participated in this particular study. The median age of these men was 59.6 (range 49.0 -89.0). All of the participants in this study gave full informed consent and were approved by Mayo Institutional Review Board. Analysis of p53AIP1 mutations in these two groups indicated thatthe Ser32Stop and Arg21 insG mutations were present in 13 of 403 (3.2%) men with sporadic prostate cancer and in 2 of 327 (0.6%) unaffected men (Table 1) , a statistically significant difference (Fisher's exact test, P = 0.016). The odds ratio was 5.4, with a 95% confidence interval of 1.2 -24.2. These results suggest that men carrying the germline p53AIP1 truncating mutations have an increased risk for developing prostate cancer by 5-6 fold.
We also examined the p53AIP1 mutations in other types of tumors. Genotyping of the two truncating mutations and the C20T (Ala7Val) missense mutation was performed in 403 tumor samples including 127 breast cancer, 110 ovarian cancer, 72 gastric cancer and 94 neuroblastomas ( Table 1) . Although the C20T missense mutation identified in prostate cancer was also present in these cancers with a similar frequency, we did not detectp53AIP1 truncating mutations in any of these non-prostate tumor samples, suggesting that the p53AIP1 truncating mutations are probably specific for prostate cancer. However, these results further support the finding of a low frequency of the 2 mutations in the population. Additional studies will be needed to analyze additional tumor types and more samples for each tumor type in order to determine whether the p53AIP1 truncating mutations are unique to prostate cancer.
The results from this study and the studies of BRCA1, BRCA2, CHEK2, and NBS1 [MIM 602667 ] in prostate cancer suggest that germline mutations in these genes involved in DNA damage-signaling pathway contribute to genetic susceptibility of prostate cancer Cybulski et al. 2004) . Although the majority of the mutations for these genes were found in sporadic prostate cancer, some of the mutations were observed in both familial and sporadic prostate cancers (Kirchhoff et al. 2004) . To explore the possibility that the two truncating mutations ofp53AIP1 might also play a role in hereditary prostate cancer, we further analyzed a total of 994 affected men and 100 unaffected men from 444 families with prostate cancer. This included 166 families collected at Mayo Clinic, 144 at Johns Hopkins, and 134 at University of Michigan . Although no truncating mutations were detected among the 100 unaffected men from these families, we detected 16 truncating mutations in 994 (1.6%) of the affected men (Table 2) . Although the data reflects a similar trend as that observed for other comparison, the frequency is lower than that detected in the sporadic cases (3.2%). Other genes may play a more prominent role for prostate cancer susceptibility in the familial cases. Clearly, additional studies are needed to explain this difference.
Since most of the genes participating in the DNA damage-signaling pathway and conferring susceptibility to prostate cancer are tumor suppressor genes, we performed loss of heterozygosity (LOH) analysis on 6 available tumors harboring p53AIP1 truncating mutations and their matched normal adjacent tissues. Analysis of the DNA isolated from Laser Capture
Microdissected tumor tissues by direct sequence revealed that loss of the wild-type alleles were present in two of the samples suggesting that p53AIP1 is a potential tumor suppressor gene (data not shown). However, the mechanism by which p53AIPJ truncating mutations contribute to prostate cancer risk is still not well defined. Recently, Matsuda et al., demonstrated that p53AIP1 is localized to the mitochondria and binds to bcl-2 thereby participating in the apoptosis pathway (Matsuda et al. 2002) . Whether the p53AIP1 mutants are able to localize to mitochondria or affect the dissipation of mitochondria membrane potential leading to apoptosis remains to be elucidated.
In conclusion, our data provide the first evidence that germline mutations inp53AIP1 may be associated with prostate cancer risk. Although we estimate the risk to be large, with an odds ratio of 5.4, the rarity of the mutations translates to a wide confidence interval in this risk, 1.2 -24.2. Larger studies are required to refine this risk estimate. These findings together with previous findings that germline mutations in four other DNA damage-responding genes (CHEK2, BRCA1, BRCA2, and NBSJ) also confer prostate cancer susceptibility in the general population, further highlights the importance of the integrity of the DNA damage-signaling pathway in prostate cancer development. Although the mechanism by which germline mutations in p53AIP1lead to prostate cancinogenesis remains to be elucidated, these mutations in prostate cancer may facilitate early diagnosis of prostate cancer and provide additional insights into the biology of this malignancy. None-the-less, independent studies will be required to further 
